Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - losartan potassium - oral tablet - 50mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - losartan potassium - oral tablet - 100mg

Kenya - Kiingereza - Pharmacy and Poisons Board

losartan potassium/ amlodipine besylate - film-coated tablet - losartan potassium usp 50mg/ amlodipine besylate… - losartan and amlodipine

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - losartan potassium - film coated tablet - 100 milligram - losartan

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - losartan potassium - film coated tablet - 50 milligram - losartan

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - losartan potassium - film coated tablet - 12.5 milligram - losartan

Kenya - Kiingereza - Pharmacy and Poisons Board

torrent pharmaceuticals ltd c/o medox… p.o.box 52771-00200 nairobi - losartan potassium amlodipine besilate - coated tablet - losartan potassium 50mg amlodipine besilate 5mg - agents acting on the renin-angiotensin system:

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - losartan potassium - film-coated tablet - 100 milligram(s) - angiotensin ii antagonists, plain; losartan

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - losartan potassium - film-coated tablet - 50 milligram(s) - angiotensin ii antagonists, plain; losartan

Marekani - Kiingereza - NLM (National Library of Medicine)

avpak - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive